Skip to main content
. 2014 Mar 6;110(8):2030–2039. doi: 10.1038/bjc.2014.88

Table 2. Patient's demographics according to ASCT2 expression in NGH cohort.

 
 
All (n=104)
AC (n=66)
Non-AC (n=38)
Variable Total (n=104) (%) High (n=66) Low (n=38) P-value High (n=36) Low (n=30) P-value High (n=30) Low (n=8) P-value
Age
⩽65 years 31 23 8 0.182 18 7 0.041 5 1 >0.999
>65 years
73
43
30
 
18
23
 
25
7
 
Sex
Male 64 46 18 0.035 19 12 0.332 27 6 0.279
Female
40
20
20
 
17
18
 
3
2
 
Smoking
Yes 66 45 21 0.209 17 14 >0.999 28 7 0.518
No
38
21
17
 
19
16
 
2
1
 
p-Stage
I or II 80 44 36 0.001 20 30 <0.001 24 6 >0.999
III or IV
24
22
2
 
16
0
 
6
2
 
T factor
T1-2 93 55 38 0.006 27 30 0.003 28 8 >0.999
T3-4
11
11
0
 
9
0
 
2
0
 
N factor
N0 71 40 31 0.030 18 25 0.009 22 6 >0.999
N1-2
33
26
7
 
18
5
 
8
2
 
Histology
AC 66 36 30 0.019
Non-AC
38
30
8
 
 
 
 
 
 
 
Lymphatic permeation
Positive 59 44 15 0.008 27 12 0.006 17 3 0.438
Negative
45
22
23
 
9
18
 
13
5
 
Vascular invasion
Positive 57 44 13 0.002 17 8 0.126 27 5 0.094
Negative
47
22
25
 
19
22
 
3
3
 
CD98
High 57 46 11 <0.001 20 4 <0.001 26 7 >0.999
Low
47
20
27
 
16
26
 
4
1
 
Ki-67
High 46 42 10 <0.001 13 5 0.099 29 5 0.024
Low
58
24
28
 
23
25
 
1
3
 
CD34
High 47 38 9 0.001 22 5 <0.001 16 4 >0.999
Low
57
28
29
 
14
25
 
14
4
 
p-mTOR
High 41 30 11 0.144 26 11 0.006 4 0 0.559
Low 63 36 27   10 19   26 8  

Abbreviations: AC=adenocarcinoma; ASCT2=ASC amino-acid transporter 2; NGH=Nishi-Gunma Hospital; non-AC=non-adenocarcinoma; p-mTOR=phosphorylation of mammalian target of rapamycin; p-stage=pathological stage.

Bold entries show statistically significant difference.